Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-Small Cell Lung Cancer
Clinical trial register · South Korea

Non-Small Cell Lung Cancer Trials in South Korea, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3401 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
3401
Studies in scope
all four open statuses
1867
Recruiting now
open to new participants
507
Lead sponsors
across recruiting studies
Top sites
Seoul 84 Suwon 34 Cheongju-si 30 Goyang-si 26 Seongnam-si 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Merck Sharp & Dohme LLC10 Hoffmann-La Roche7 AbbVie5 Eli Lilly and Company4 Bristol-Myers Squibb4 Yonsei University3 Samsung Medical Center3 Boehringer Ingelheim2 BioNTech SE2 Daiichi Sankyo2 Gilead Sciences2 Konkuk University Medical Center1 Pusan National University Hospital1 InSightec1 Regeneron Pharmaceuticals1 Nuvalent Inc.1 Amgen1 GeneCraft Inc.1 BicycleTx Limited1 Cullinan Therapeutics Inc.1 Genentech, Inc.1 Pierre Fabre Medicament1 Klus Pharma Inc.1 Inhibrx Biosciences, Inc1 Show all 39
Site location
Seoul84 Suwon34 Cheongju-si30 Goyang-si26 Seongnam-si22 Incheon19 Busan14 Seongnam14 Daegu13 Gyeonggi-do9 Jinju8 Daejeon7 Yangsan7 Hwasun6 Jeollanam-do5 Namdong-gu3 Goyang3 Hwasun-gun3 Soeul2 Ulsan2 Bupyeong-gu2 Changwon-si2 Deagu2 Inchon2 Chungcheongbuk-do1 Show all 45
All 45 locations
Target enrolment
to

Non-Small Cell Lung Cancer trials in South Korea

86 of 3401 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Bristol-Myers Squibb
Observational
10
Seoul
2026-10-31
Recruiting
Hoffmann-La Roche
Phase 3
400
Seongnam-si, Busan, Daegu, Daejeon, Gyeonggi-do, Incheon, Jeollanam-do, Seoul
2026-10-06
Recruiting
Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
NCT07921888Non-Small Cell Lung Cancer, Minimal Residual Disease
Eun Hye Lee
Observational
40
Yongin-si, Seoul
2026-09-28
Recruiting
Bristol-Myers Squibb
Phase 3
850
Cheongju-si, Buk-Gu, Dalseo, Goyang-si, Seongnam-si, Hwasun-Gun, Seocho -Gu, Songpa-Gu
2026-09-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Goyang-si, Suwon, Cheongju-si, Daegu, Seoul
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul
2026-05-04
Recruiting
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
NCT07423117Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic Solid Tumor
IntoCell, Inc
Phase 1
102
Seoul
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Goyang-si, Suwon, Daegu, Seoul
2026-03-18
Recruiting
Boehringer Ingelheim
Phase 3
400
Goyang, Seongnam, Seoul, Suwon
2026-01-16
Recruiting
STCube, Inc.
Phase 2
62
Gyeonggi-do, Seoul
2026-01-10
Recruiting
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
NCT07358806Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer
Oscotec Inc.
Phase 1
51
Goyang-si, Seongnam-si, Seoul
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Suwon, Hwasun, Incheon, Seoul
2025-12-17
Recruiting
AbbVie
Phase 2/3
490
Goyang-si, Cheongju-si, Seoul
2025-12-10
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Seoul
2025-11-21
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
Cheongju-si, Goyang-si, Seongnam, Suwon, Seoul
2025-11-05
Recruiting
Daiichi Sankyo
Phase 3
686
Cheongju-si, Goyang-si, Jinju, Seongnam, Seoul, Suwon
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Busan, Cheongju-si, Daegu, Seoul
2025-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Jeollanam-do, Yangsan, Busan, Daejeon, Seoul
2025-10-08
Recruiting
AstraZeneca
Phase 2
278
Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-08-07
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Seoul
2025-07-29
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
404
Seoul
2025-07-25
Recruiting
Pfizer
Phase 3
714
Hwasun-gun, Seongnam, Suwon, Busan, Haeundae-gu, Seoul, Deagu
2025-07-23
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Cheongju-si, Goyang-si, Incheon, Seoul
2025-07-17
Recruiting
Pusan National University Hospital
Phase 2
70
Busan
2025-07-01
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gyeonggi-do, Cheongju-si, Hwasun, Seoul
2025-05-06
Not yet open
GeneCraft Inc.
Phase 1
18
Seoul
2025-05
Recruiting
BioNTech SE
Phase 2
60
Jinju, Cheongju-si, Incheon, Seoul
2025-03-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
2025-01-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Pusan Kwangyokshi, Daejeon, Seoul
2024-11-21
Recruiting
AstraZeneca
Phase 3
1,160
Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon
2024-11-18
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Active, closed
Hoffmann-La Roche
Phase 3
338
Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2024-09-23
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
Ilsandong-gu, Seoul, Suwon
2024-09-19
Active, closed
Amgen
Phase 1
49
Seoul
2024-09-17
Active, closed
AstraZeneca
Phase 2
194
Seongnam, Seoul, Suwon
2024-08-27
Recruiting
Anesthesia and Non-small Cell Lung Cancer Recurrence
NCT06330038Non-small Cell Lung Cancer, Surgery, Anesthesia
DrugsAnesthetics·Isoflurane·Desflurane·Sevoflurane
Samsung Medical Center
Phase 4
5,384
Seoul
2024-08-05
By invitation
Yonsei University
Phase 2
27
Seoul
2024-07-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bupyeong-gu, Yangsan, Busan, Deagu, Daejeon, Seoul
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Bupyeong-gu, Hwasun, Suwon, Yangsan, Daegu, Junggu, Incheon, Seoul
2024-05-24
Recruiting
AstraZeneca
Phase 3
582
Goyang-si, Namdong-gu, Seoul, Suwon
2024-04-29
Recruiting
AstraZeneca
Phase 3
675
Changwon, Incheon, Seongnam-si, Seoul, Suwon
2024-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2024-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Goyang-si, Seongnam, Suwon, Cheongju-si, Daegu, Seoul
2023-12-06
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Cheongju-si, Goyang-si, Seongnam-si, Seoul
2023-09-26
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Seongnam-si, Suwon, Incheon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-08-08
Active, closed
OncoC4, Inc.
Phase 3
630
Cheongju-si, Daegu, Goyang-si, Seoul, Suwon
2023-06-28
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Busan, Seoul
2023-06-20
Active, closed
Klus Pharma Inc.
Phase 2
356
Suwon, Cheongju-si, Seoul, Busan
2023-04-19
Active, closed
Hoffmann-La Roche
Phase 3
68
Daegu, Gyeongsangnam-do, Jeollanam-do, Seongnam-si, Seoul
2022-11-01
Active, closed
Gilead Sciences
Phase 3
1,021
Gangnam-Gu, Goyang, Heungdeok-Gu, Inchon, Seoul, Suwon
2022-10-12
Active, closed
Yonsei University
Phase 2
25
Seoul
2022-09-01
Recruiting
InSightec
Phase 3
96
Seoul, Soeul
2022-08-12
Active, closed
Gilead Sciences
Phase 2
193
Cheongju-si, Inchon, Seoul, Suwon
2022-05-30
Recruiting
Konkuk University Medical Center
Phase 2
40
Seoul
2022-05-19
Recruiting
AstraZeneca
Phase 2
630
Busan, Chungcheongbuk-do, Seongnam-si, Seoul, Suwon
2022-04-14
Recruiting
AbbVie
Phase 3
768
Goyang-si, Seongnam, Suwon, Jinju, Yangsan, Cheongju-si, Seoul
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Daegu, Jinju, Seoul, Suwon
2022-02-21
Active, closed
AstraZeneca
Phase 3
791
Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2022-02-18
Active, closed
AstraZeneca
Phase 3
1,051
Changwon-si, Cheongju-si, Seongnam-si, Seoul, Suwon
2022-02-07
Active, closed
Yonsei University
Phase 2
160
Seoul
2022-02-07
Recruiting
AbbVie
Phase 1
694
Goyang-si, Seongnam, Seoul
2021-11-01
Active, closed
AbbVie
Phase 1
520
Busan, Seongnam, Jinju, Cheongju-si, Seoul
2021-10-13
Active, closed
Nuvation Bio Inc.
Phase 2
217
Busan, Gyeongsang, Hwasun, Seoul
2021-09-01
Recruiting
Boehringer Ingelheim
Phase 1
554
Chungju, Seongnam, Seoul
2021-07-02
Active, closed
Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery
NCT04536675Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer
Samsung Medical Center
Phase 3
204
Seoul
2021-04-01
Active, closed
Daiichi Sankyo
Phase 3
605
Cheongju-si, Daegu, Gyeonggi-do, Seongnam-si, Seoul
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Daegu, Hwasun-gun, Incheon, Seoul, Yangsan
2020-12-16
Active, closed
Genentech, Inc.
Phase 1
498
Seongnam-si, Seoul
2020-07-29
Active, closed
Eli Lilly and Company
Phase 3
261
Goyang-si, Seongnam-si, Incheon, Seoul, Jinju, Dongjak-gu, Daejeon
2020-02-17
Recruiting
Inhibrx Biosciences, Inc
Phase 1/2
340
Busan, Cheongju-si, Gyeonggi-do, Hwasun, Incheon, Seongnam-si, Seoul, Suwon
2019-12-10
Active, closed
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
DrugTobemstomig
Hoffmann-La Roche
Phase 1/2
170
Seongnam-si, Seoul
2019-11-11
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
Incheon, Seoul
2019-11-07
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
Goyang-si, Gyeonggi-do, Incheon, Seoul, Soeul, Suwon
2019-10-31
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Cheonju, Goyang, Seongnam, Seoul, Suwon
2019-07-09
Active, closed
AstraZeneca
Phase 3
587
Cheongju-si, Goyang-si, Seoul
2019-07-02
Active, closed
AstraZeneca
Phase 2
247
Seongnam-si, Seoul
2019-06-25
Active, closed
AstraZeneca
Phase 3
825
Busan, Cheongju-si, Seongnam-si, Seoul, Suwon
2018-12-06
Active, closed
AbbVie
Phase 2
270
Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Gyeonggi-do, Seoul
2018-04-24
Active, closed
AstraZeneca
Phase 2
528
Seoul
2017-12-18
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Gyeonggi-do, Jeollanam-do, Seoul
2017-09-22
Recruiting
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
NCT03791034Non-small Cell Lung Cancer
Samsung Medical Center
Observational
700
Seoul
2017-08-28
Active, closed
Eli Lilly and Company
Phase 1/2
857
Goyang-si, Seongnam, Seoul
2017-05-02
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Seoul
2016-06
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Cheongju-si, Goyang-si, Incheon, Seongnam-si, Seoul
2016-05-24
Active, closed
Eli Lilly and Company
Phase 3
453
Goyang-si, Incheon, Seoul, Seowon-Gu, Suwon, Ulsan
2014-10-03
Rows per page Showing 1–86 of 86
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-south-korea/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,401 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 86 of those studies listing the condition Non-Small Cell Lung Cancer.

How many Non-Small Cell Lung Cancer trials are recruiting in South Korea?

44 of the 86 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 2 have not yet opened recruitment, 39 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Small Cell Lung Cancer), 86 studies
PhaseStudiesRecruitingShare
Phase 3402246.5%
Phase 216618.6%
Phase 112614%
Phase 1/29410.5%
Phase 2/3535.8%
Observational323.5%
Phase 4111.2%

Most active sponsors

Lead sponsors with the most studies (Non-Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca156
Merck Sharp & Dohme LLC107
Hoffmann-La Roche73
AbbVie53
Bristol-Myers Squibb43
Eli Lilly and Company40
Samsung Medical Center32
Yonsei University30
BioNTech SE22
Boehringer Ingelheim22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.